source
- Compass Therapeutics reports secondary endpoint data from pivotal biliary tract cancer trial, shares stock dropCompass Therapeutics announced new secondary‑endpoint results from its pivotal bispecific antibody trial in second‑line biliary tract cancer, a year after reporting a Phase 2/3 success. The additi…
- Erasca releases early-stage RAS drug data amid legal dispute with Revolution MedicinesErasca has released early-stage data on its RAS-targeting compound, doing so after receiving a legal threat from rival Revolution Medicines. Revolution recently announced a new drug that revived h…